Pacira BioSciences, Inc. (PCRX)
NASDAQ$22.87
Market Cap
$1.06B
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
235 of 924
Rank in Industry
10 of 56
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
PCRX Insider Trading Activity
PCRX Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $215,684 | 6 | 38 |
Sells | $653,601 | 10 | 62 |
Related Transactions
| Lee Frank D. | Chief Executive Officer | 1 | $99,994 | 0 | $0 | $99,994 |
| BIGAL MARCELO | director | 2 | $60,868 | 0 | $0 | $60,868 |
| YANG MICHAEL J. | director | 1 | $25,800 | 0 | $0 | $25,800 |
| Froimson Mark | director | 1 | $16,212 | 0 | $0 | $16,212 |
| Brege Laura | director | 1 | $12,810 | 0 | $0 | $12,810 |
| HASTINGS PAUL J | director | 0 | $0 | 1 | $24,974 | $-24,974 |
| GAUGLER DARYL | Chief Operating Officer | 0 | $0 | 3 | $44,690 | $-44,690 |
| RIKER LAUREN | Senior Vice President, Finance | 0 | $0 | 1 | $114,018 | $-114,018 |
| WILLIAMS KRISTEN | Chief Administrative Officer | 0 | $0 | 1 | $211,488 | $-211,488 |
| SLONIN JONATHAN | Chief Medical Officer | 0 | $0 | 4 | $258,431 | $-258,431 |
About Pacira BioSciences, Inc.
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that …
Insider Activity of Pacira BioSciences, Inc.
Over the last 12 months, insiders at Pacira BioSciences, Inc. have bought $215,684 and sold $653,601 worth of Pacira BioSciences, Inc. stock.
On average, over the past 5 years, insiders at Pacira BioSciences, Inc. have bought $215,684 and sold $17.1M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Lee Frank D. (Chief Executive Officer) — $99,994. BIGAL MARCELO (director) — $60,868. YANG MICHAEL J. (director) — $25,800.
The last purchase of 1,512 shares for transaction amount of $20,034 was made by BIGAL MARCELO (director) on 2024‑08‑16.
List of Insider Buy and Sell Transactions, Pacira BioSciences, Inc.
| 2025-01-06 | Sale | SLONIN JONATHAN | Chief Medical Officer | 879 0.0019% | $18.40 | $16,174 | +33.25% | |
| 2024-12-13 | Sale | GAUGLER DARYL | Chief Operating Officer | 500 0.0011% | $19.76 | $9,880 | +17.04% | |
| 2024-09-13 | Sale | GAUGLER DARYL | Chief Operating Officer | 500 0.0011% | $12.86 | $6,430 | +43.10% | |
| 2024-08-16 | Brege Laura | director | 1,000 0.0023% | $12.81 | $12,810 | +36.24% | ||
| 2024-08-16 | BIGAL MARCELO | director | 1,512 0.0036% | $13.25 | $20,034 | +36.24% | ||
| 2024-08-14 | YANG MICHAEL J. | director | 2,000 0.0046% | $12.90 | $25,800 | +40.74% | ||
| 2024-08-12 | Lee Frank D. | Chief Executive Officer | 8,264 0.0178% | $12.10 | $99,994 | +42.39% | ||
| 2024-08-12 | Froimson Mark | director | 1,400 0.0029% | $11.58 | $16,212 | +42.39% | ||
| 2024-08-12 | BIGAL MARCELO | director | 3,400 0.0073% | $12.01 | $40,834 | +42.39% | ||
| 2024-08-02 | Sale | SLONIN JONATHAN | Chief Medical Officer | 945 0.0019% | $20.05 | $18,947 | -17.45% | |
| 2024-07-02 | Sale | SLONIN JONATHAN | Chief Medical Officer | 2,836 0.0062% | $28.25 | $80,117 | -17.15% | |
| 2024-06-13 | Sale | GAUGLER DARYL | Chief Operating Officer | 1,000 0.0021% | $28.38 | $28,380 | -32.32% | |
| 2024-06-13 | Sale | WILLIAMS KRISTEN | Chief Administrative Officer | 7,452 0.0157% | $28.38 | $211,488 | -32.32% | |
| 2024-06-13 | Sale | HASTINGS PAUL J | director | 880 0.0019% | $28.38 | $24,974 | -32.32% | |
| 2024-06-12 | Sale | RIKER LAUREN | Senior Vice President, Finance | 3,970 0.0085% | $28.72 | $114,018 | -32.93% | |
| 2024-06-11 | Sale | SLONIN JONATHAN | Chief Medical Officer | 5,012 0.0106% | $28.57 | $143,193 | -33.48% | |
| 2024-03-08 | Sale | PACE GARY W | director | 90,000 0.1889% | $30.60 | $2.75M | -32.73% | |
| 2024-03-07 | Sale | PACE GARY W | director | 28,257 0.0613% | $30.81 | $870,598 | -30.83% | |
| 2024-03-06 | Sale | PACE GARY W | director | 1,066 0.0023% | $29.67 | $31,628 | -29.61% | |
| 2023-08-02 | Sale | WINSTON ROY | Chief Medical Officer | 509 0.0011% | $34.88 | $17,751 | -19.83% |
Total: 430
*Gray background shows transactions not older than one year
Insider Historical Profitability
22.98%
| Lee Frank D. | Chief Executive Officer | 107784 0.2329% | $2.47M | 1 | 0 | |
| Brege Laura | director | 17552 0.0379% | $401,414.24 | 1 | 6 | |
| Froimson Mark | director | 14473 0.0313% | $330,997.51 | 2 | 2 | <0.0001% |
| HASTINGS PAUL J | director | 12724 0.0275% | $290,997.88 | 1 | 18 | +79.52% |
| BIGAL MARCELO | director | 10142 0.0219% | $231,947.54 | 2 | 0 |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$910,099,463 | 123 | 11.52% | $2.63B | |
$187,390,806 | 89 | 12.63% | $777.44M | |
$12,681,496 | 70 | 20.90% | $804.92M | |
$14,599,168 | 59 | 12.79% | $1.36B | |
$23,522,750 | 59 | -6.74% | $5.16B |
PCRX Institutional Investors: Active Positions
| Increased Positions | 114 | +39.86% | 8M | +15.58% |
| Decreased Positions | 122 | -42.66% | 10M | -18.54% |
| New Positions | 37 | New | 3M | New |
| Sold Out Positions | 44 | Sold Out | 2M | Sold Out |
| Total Postitions | 278 | -2.8% | 50M | -2.96% |
PCRX Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Blackrock, Inc. | $185,421.00 | 16.76% | 7.71M | -77,580 | -1% | 2024-12-31 |
| Vanguard Group Inc | $126,597.00 | 11.44% | 5.26M | -34,764 | -0.66% | 2024-12-31 |
| Pacer Advisors, Inc. | $78,471.00 | 7.09% | 3.26M | -2M | -34.25% | 2024-12-31 |
| D. E. Shaw & Co., Inc. | $54,292.00 | 4.91% | 2.26M | +300,536 | +15.36% | 2024-12-31 |
| Renaissance Technologies Llc | $47,922.00 | 4.33% | 1.99M | +13,604 | +0.69% | 2024-12-31 |
| State Street Corp | $47,270.00 | 4.27% | 1.97M | -48,544 | -2.41% | 2024-12-31 |
| Dimensional Fund Advisors Lp | $44,065.00 | 3.98% | 1.83M | -40,154 | -2.15% | 2024-12-31 |
| Doma Perpetual Capital Management Llc | $42,036.00 | 3.8% | 1.75M | 0 | 0% | 2024-12-31 |
| Millennium Management Llc | $35,727.00 | 3.23% | 1.49M | +879,473 | +145.12% | 2024-12-31 |
| Ubs Group Ag | $33,064.00 | 2.99% | 1.37M | +1M | +620.71% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.